Vision & Mission
Vision
Every lung disease patient diagnosed & treated at the earliest possible stage with the best treatment
It’s about finding the patients, many of whom are asymptomatic, and accelerating their time to diagnosis, care and ultimately cure.
Dr. Daniel Miller, Director of Thoracic Surgery at Georgia Cancer Center
Mission
Our lung AI precision-care platform powering earlier diagnosis, better treatment decisions & life-saving surgery in every hospital
Mission
Our lung AI precision-care platform powering earlier diagnosis, better treatment decisions & life-saving procedures in every hospital
As with just about any health problem, knowing earlier gives you and your healthcare provider the opportunity to intervene... [before] treatment options are limited
Dr. MeiLan Han, Professor of Medicine and pulmonologist at University of Michigan
Hear from one of our founders
Dr Lyndsey Pickup
Head of Clinical Evidence
& co-founder
& co-founder
I lead the Clinical Evidence team at Optellum. We handle two big areas within the business. First, we work on publishing evidence demonstrating the value of Optellum's innovations. These studies play a crucial role in gaining the trust of clinicians, academic and industry partners, and ultimately of patients and their families. Secondly, we handle the bespoke curation and detailed understanding of the huge medical imaging datasets driving our technical innovation, because even the best AI model out there needs quality data to learn from. In a world full of bias, that's a really pertinent problem to work on for the good of everyone equitably.
I co-founded Optellum because I could see how much benefit machine learning technology could bring to understanding lung data, and growing Optellum is the best way to put these cutting-edge innovations where they can really benefit patients.
I co-founded Optellum because I could see how much benefit machine learning technology could bring to understanding lung data, and growing Optellum is the best way to put these cutting-edge innovations where they can really benefit patients.
Our history
2016
Optellum founded
Founded by former Oxford University Computer Vision lab scientists
2019
VC-led seed round
$4 million for further clinical evidence & regulatory clearance
2021
Regulatory clearance in UK & US for VNC
510(k) clearance with FDA and CE / UKCA marking
Large-cap MedTech partnership deal
Fuel development of pulmonology indications-for-use expansion
2023
Large-cap Pharma partnership
deal
Development of novel AI-enabled therapy guidance
Strategic MedTech pilot project start
Multi-site deployment & post-market evidence generation
Zero-click LCP AI ready for clearance
Automated nodule detector helping expand suite of offerings
2018
Optellum Virtual Nodule Clinic® & LCP AI ready
Pre-market feedback obtained
2020
Publications with top KOLs
First external validation studies published
2022
VC-led series A funding
$14 million to expand team and commercialize
CPT codes & CMS payment classification
Medicare reimbursement generating more ROI for hospitals
Large-cap MedTech distribution
deal
Strategic partnership for worldwide distribution
2024
World's largest chest CT dataset
Key milestones reached in NHS-led DART study
AI therapy guidance platform launch
LCP-ROR (risk of recurrence) outperforms standard staging
Guideline-relevant evidence publication
LCP AI outperforms standard-of-care clinical risk models
Real-world impact results
Real-world customer results show transformative patient benefit
2016
Optellum founded
Founded by scientists at Oxford University’s computer vision lab
2018
Virtual Nodule Clinic & LCP AI® v1 ready
Pre-market feedback obtained
2019
VC-led seed round
$4 million for further clinical evidence & regulatory clearance
2020
Publications with top KOLs
First external validation studies published
2021
Regulatory clearance in UK & US for VNC
510(k) clearance with FDA and CE / UKCA marking
Large-cap MedTech partnership deal
Fuel development of pulmonology indications-for-use expansion
2022
VC-led series A funding
$14 million to expand team and commercialize
CPT codes & CMS payment classification
Medicare reimbursement generating more ROI for hospitals
Large-cap MedTech distribution
deal
Strategic partnership for worldwide distribution
2023
Large-cap Pharma partnership
deal
Development of novel AI-enabled therapy guidance
Strategic MedTech pilot project start
Multi-sites deployment & post-market evidence generation
Zero-click LCP AI® ready for clearance
Automated nodule detector helping expand suite of offerings
2024
World's largest chest CT dataset
Key milestones reached in NHS-led DART study
AI therapy guidance platform launch
LCP-ROR (risk of recurrence prediction) outperforms standard staging
Guideline-relevant evidence publication
LCP AI® outperforms standard-of-care clinical risk models
Real-world impact results
Florida & NJ pilot site results show transformative patient benefit
Careers at Optellum
We’re building an exceptional team to shape the future of early intervention in lung cancer and lung disease
Join our teamOptellum is trusted by industry & academic leaders
Certification
Redefining early intervention of lung disease
starting with one of the deadliest, lung cancer
Contact us